Quarterly Due End of Month, page-9

I don't believe their is any real expectation of significant revenue being shown in the Quarterly

When we were 40c their was expectation that revenue would be flowing but failed approvals has us now valued with zilch revenue being generated.

The market has us currently valued as a R&D company

Successful Alfred and Madrid trials and subsequent TGA / Europe and FDA approvals would see our share price increase as it opens up the doors to start sales flowing. But given our inability yet to get approvals , and seeing what failure results in (Lumos anyone ?) means few will take a punt on us now until we deliver.

And once we do , with Ellume busy overseas and Lumos dead , we are prime candidates for soverign manufacturing funding.

Let's hope our 1/4ly at least elaborates on all the " collaborations" and gives some insight into what the pathway is for commercialising our technology.

Only a deal can re-establish our credibility ...

And once you get 1 over the line , FOMO can see deals start to flow in rapid succession.

Good luck to all.